Suppr超能文献

韩国腹膜透析的现状:为实现最佳治疗效果所做的努力。

Current status of peritoneal dialysis in Korea: efforts to achieve optimal outcome.

作者信息

Han D S, Hwang J H, Kang D H, Song H Y, Noh H, Shin S K, Lee S W, Kang S W, Choi K H, Ha S K, Lee H Y

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Perit Dial Int. 1999;19 Suppl 3:S17-25.

Abstract

Since its introduction in 1981, peritoneal dialysis (PD) has become firmly established as an effective mode of renal replacement therapy and serves an increasing patient population in Korea. The latest registry data indicate that about 3700 end-stage renal disease patients are maintained on chronic PD, representing 24.1% of the country's dialysis population. The majority (93.3%) of these patients are on continuous ambulatory peritoneal dialysis (CAPD) using the two-bag disconnect system, while only 3.3% are on automated PD. Under current renal reimbursement policies, most dialysis patients have to pay 20% of dialysis fees. Thus CAPD patients on 4 x 2-L daily exchanges pay about US$200 per month, not including medication and travel costs. Traditionally, most PD centers in Korea have used the "standard" prescription of 4 exchanges of 2 L of solution for most of their patients. A recent survey of 1467 patients who commenced CAPD in 1997 revealed that 84% of these patients were initially prescribed 4 x 2-L exchanges, while 12% were given a daily volume of 6 L. With this standard prescription, the percentages of Korean CAPD patients initially achieving the adequacy target of Kt/V urea > or = 2.0 and standardized creatinine clearance (SCCr) > or = 60 L/week/1.73 m2, were 74.4% and 82.1%, respectively. It is likely that, among current Korean CAPD patients, a much lower percentage will achieve the clearance targets compared to this initial outcome, but the precise data are not available. However, it is not clear whether the levels of small-solute clearance recommended for optimal PD outcomes, and proposed by the NKF-DOQI guidelines, will bring the expected benefits to Korean patients. Overall survival of Korean PD patients appears to be as good as, or even better than, that in most other countries. Recently, a single large PD center reported patient survival of 92.1%, 85.6%, 81.4%, and 67.6% at 1, 2, 3, and 5 years respectively. Other centers also reported similar outcomes. As in other countries, cardiovascular deaths predominate among Korean patients: death was due to cardiac causes in 29%, to vascular causes in 21%, and to infectious causes in 24%. Peritonitis is the most important barrier to prolonged use of CAPD in Korea, and more PD patients transfer to hemodialysis because of peritonitis than in other countries. To further reduce the morbidity and mortality of Korean PD patients, various control measures need to be implemented that can reduce or prevent peritonitis and other infectious complications. Also, to further improve long-term patient outcome, Korean nephrologists need to establish and practice optimal clearance targets in the chronic care of these patients.

摘要

自1981年引入以来,腹膜透析(PD)已成为一种成熟的有效肾脏替代治疗方式,在韩国接受治疗的患者人数不断增加。最新登记数据显示,约3700例终末期肾病患者接受维持性慢性腹膜透析治疗,占该国透析患者总数的24.1%。这些患者中的大多数(93.3%)采用双袋断开系统进行持续性非卧床腹膜透析(CAPD),而只有3.3%的患者接受自动化腹膜透析。根据目前的肾脏报销政策,大多数透析患者需自行承担20%的透析费用。因此,每日进行4次2L交换的CAPD患者每月需支付约200美元,这还不包括药物和交通费用。传统上,韩国的大多数腹膜透析中心对大多数患者采用“标准”处方,即每日进行4次2L溶液交换。最近一项针对1997年开始接受CAPD治疗的1467例患者的调查显示,其中84%的患者最初被处方为每日4次2L交换,而12%的患者每日交换量为6L。按照这个标准处方,韩国CAPD患者最初达到尿素Kt/V≥2.0以及标准化肌酐清除率(SCCr)≥60L/周/1.73m²充分性目标的比例分别为74.4%和82.1%。与最初的结果相比,目前韩国CAPD患者中达到清除目标的比例可能要低得多,但尚无确切数据。然而,目前尚不清楚美国国家肾脏基金会-透析结果质量倡议(NKF-DOQI)指南所推荐且被认为是最佳腹膜透析结果的小分子溶质清除水平,是否会给韩国患者带来预期的益处。韩国腹膜透析患者的总体生存率似乎与大多数其他国家相当,甚至更好。最近,一个大型腹膜透析中心报告称,患者1年、2年、3年和5年的生存率分别为92.1%、85.6%、81.4%和67.6%。其他中心也报告了类似的结果。与其他国家一样,韩国患者的死亡主要原因是心血管疾病:29%的患者死于心脏原因,21%死于血管原因,24%死于感染原因。在韩国,腹膜炎是影响CAPD长期使用的最重要障碍,因腹膜炎而转为血液透析的腹膜透析患者比其他国家更多。为了进一步降低韩国腹膜透析患者的发病率和死亡率,需要实施各种控制措施,以减少或预防腹膜炎及其他感染并发症。此外,为了进一步改善患者的长期预后,韩国肾脏病学家需要在这些患者长期护理中确立并实践最佳清除目标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验